| Short facts | |
| API | Ketorolac |
| Technology | Sublingual |
| Indication | Moderate to moderately severe pain |
| Development phase | Finalized phase 1 |
| Expected filing with FDA | - |
| In-house or partnership | In-house |
Unmet need
Opioids are still used unnecessarily in many situations, further fueling the opioid crisis.
Our aim
Based on Orexo´s novel oral formulation technology, the aim is to develop an opioid-level pain relief treatment for short-term pain (up to 5 days) without the risk of addiction.
Differentiation
Results from the exploratory PK-study in healthy volunteers showed significant better PK-profile, such as faster uptake and higher peak, when compared to nasal spray available on the market.